SBIR-STTR Award

High Throughput Rnai Based Functional Genomics in Primary Cells and in Vivo
Award last edited on: 1/26/18

Sponsored Program
SBIR
Awarding Agency
NIH : NHGRI
Total Award Amount
$1,576,400
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Alexey Wolfson

Company Information

AdviRNA LLC (AKA: Advanced RNA Technologies LLC)

Mbi At Gateway Park 60 Prescott Street
Worcester, MA 01605
   (508) 796-5216
   info@advirna.com
   www.advirna.com
Location: Single
Congr. District: 02
County: Worcester

Phase I

Contract Number: 1R44HG006788-01
Start Date: 8/1/12    Completed: 1/31/13
Phase I year
2012
Phase I Amount
$281,400
Completion of the HGP (human genome program) has opened the 'Genomic Era' in biomedical research and enables functional genomics analysis of various gene elements. The long-term goal of the ENCODE Project is to identify and functionally characterize all of the sequence-based genomic elements. Functional elements that have been studied in ENCODE include transcribed sequences, regulators of transcription, and regulators of RNA transcripts themselves. The function of more than 50% of transcribed gene sequences is unknown. Most of them are expressed in specialized cells and thus their functions can only be studied in a biologically relevant context (i.e. primary cells, in vivo). In this propoal we plan to develop and commercialize a new RNAi platform that enables gene studies in a biologically relevant context with a long term goal of building a functional map of human genome. Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in efficient gene silencing. siRNA-based functional genomics is widely used in established cell lines in vitro, but its applicability to primary cells and in vivo target validatin has been limited because of lack of efficient and non-toxic delivery systems. In collaboration with RXi pharmaceuticals we have developed a novel class of RNAi compounds - self deliverable RNAs. These small, asymmetric, hydrophobically modified RNA compounds enter cells and tissues without requirement for delivery formulation and efficiently silence genes in vitro and in vivo, enabling functional genomics studies in primary cells, embryonic cells, tissues, ex vivo, and in vivo. The major technical hurdle, which impedes wide spread use of this platform by scientific community is the complex and costly process of compound identification, synthesis and validation. The focus of this fast-track proposal is optimization of compound discovery process (Phase I) and development of a panel of 200-1000 functionally validated sdRNAs (Phase II), Completion of this proposal will build a commercially available product platform that will revolutionize functional genomics studies in biologically relevant systems such as primary cells, stem cells, tissue and organ models and eventually in vivo.

Public Health Relevance Statement:
This proposal is focused on development and commercialization of a new RNAi platform that enables gene studies in a biologically relevant context with a long term goal of building a functional map of human genome. sdRNAs are small, asymmetric, hydrophobically modified compounds that enter cell and tissues without requirement for delivery formulation and efficiently silence genes in vitro and in vivo. The focus of this proposal is developing and making available to scientific community a panel of 200-1000 of sdRNA compounds to enable HTS functional genomics analysis in primary cells, stem cells, tissues and in vivo.

NIH Spending Category:
Bioengineering; Biotechnology; Genetics; Human Genome

Project Terms:
Algorithms; Area; Automation; base; Base Sequence; Bioinformatics; Biomedical Research; blastomere structure; cell type; Cells; Chemistry; Collaborations; commercialization; Communities; Complex; cost; Custom; Data Set; Databases; design; Development; Drug Formulations; Elements; Environment; Equipment and supply inventories; established cell line; functional genomics; Funding; gene function; Gene Silencing; Genes; Genetic Transcription; Genomics; Goals; high throughput screening; Human Genome; Immunology; improved; In Vitro; in vivo; in vivo Model; Inflammation; Inflammatory; Libraries; Maps; Messenger RNA; Methods; Neurobiology; novel; oncology; Organ Model; parallel processing; Pathway interactions; Pharmacologic Substance; Phase; Process; programs; Reagent; Reporter; Research; Research Infrastructure; Research Methodology; Research Personnel; RNA; RNA Interference; scaffold; Screening procedure; Small Interfering RNA; Stem cells; Structure; success; System; Technology; text searching; Time; Tissue Model; Tissues; tool; Transcript; Transcriptional Regulation; Transfection; uptake; Validation; web based interface

Phase II

Contract Number: 4R44HG006788-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2014
(last award dollars: 2015)
Phase II Amount
$1,295,000

Completion of the HGP (human genome program) has opened the 'Genomic Era' in biomedical research and enables functional genomics analysis of various gene elements. The long-term goal of the ENCODE Project is to identify and functionally characterize all of the sequence-based genomic elements. Functional elements that have been studied in ENCODE include transcribed sequences, regulators of transcription, and regulators of RNA transcripts themselves. The function of more than 50% of transcribed gene sequences is unknown. Most of them are expressed in specialized cells and thus their functions can only be studied in a biologically relevant context (i.e. primary cells, in vivo). In this propoal we plan to develop and commercialize a new RNAi platform that enables gene studies in a biologically relevant context with a long term goal of building a functional map of human genome. Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in efficient gene silencing. siRNA-based functional genomics is widely used in established cell lines in vitro, but its applicability to primary cells and in vivo target validatin has been limited because of lack of efficient and non-toxic delivery systems. In collaboration with RXi pharmaceuticals we have developed a novel class of RNAi compounds - self deliverable RNAs. These small, asymmetric, hydrophobically modified RNA compounds enter cells and tissues without requirement for delivery formulation and efficiently silence genes in vitro and in vivo, enabling functional genomics studies in primary cells, embryonic cells, tissues, ex vivo, and in vivo. The major technical hurdle, which impedes wide spread use of this platform by scientific community is the complex and costly process of compound identification, synthesis and validation. The focus of this fast-track proposal is optimization of compound discovery process (Phase I) and development of a panel of 200-1000 functionally validated sdRNAs (Phase II), Completion of this proposal will build a commercially available product platform that will revolutionize functional genomics studies in biologically relevant systems such as primary cells, stem cells, tissue and organ models and eventually in vivo.

Thesaurus Terms:
Algorithms;Area;Automation;Base;Base Sequence;Bioinformatics;Biomedical Research;Blastomere Structure;Cell Type;Cells;Chemistry;Collaborations;Commercialization;Communities;Complex;Cost;Custom;Data Set;Databases;Design;Development;Drug Formulations;Elements;Environment;Equipment And Supply Inventories;Established Cell Line;Functional Genomics;Funding;Gene Function;Gene Silencing;Genes;Genetic Transcription;Genomics;Goals;High Throughput Screening;Human Genome;Immunology;Improved;In Vitro;In Vivo;In Vivo Model;Inflammation;Inflammatory;Libraries;Maps;Messenger Rna;Methods;Neurobiology;Novel;Oncology;Organ Model;Parallel Processing;Pathway Interactions;Pharmacologic Substance;Phase;Process;Programs;Reagent;Reporter;Research;Research Infrastructure;Research Methodology;Research Personnel;Rna;Rna Interference;Scaffold;Screening;Small Interfering Rna;Stem Cells;Structure;Success;System;Technology;Text Searching;Time;Tissue Model;Tissues;Tool;Transcript;Transcriptional Regulation;Transfection;Uptake;Validation;Web Based Interface;